Oral Rivaroxaban Reduces Risk of Recurrent VTE with No Increase in Bleeding

Oral rivaroxaban’s efficacy at reducing the risk of recurrent venous thromboembolism (VTE) was confirmed in two trials presented at the annual meeting of the American Society of Hematology. The agent was studied for treatment of deep-vein thrombosis (DVT) as well as for continued therapy after initial anticoagulation treatment for DVT or pulmonary embolism.
 
For the DVT study, the EINSTEIN Investigators randomized 3449 patients with symptomatic DVT to rivaroxaban or enoxaparin plus either warfarin or acenocoumarol for 3, 6, or 12 months. Rivaroxaban was taken twice daily (15 mg) for 3 weeks, with a maintenance dose (20 mg daily) for the remainder of the study period. Enoxaparin was taken at a weight-adjusted dose until the international normalized ratio was 2 or greater for 2 days and after a minimum of 5 days of treatment. Patients in both groups received a vitamin K antagonist throughout the study period.
 
Rivaroxaban significantly reduced DVT risk over enoxaparin (P <.001). Major bleeding or clinically relevant nonmajor bleeding, the primary safety outcome, occurred in 8.1% of patients in both groups.
 
For the continuation study, the investigators randomized 1200 patients with symptomatic DVT or pulmonary embolism who had been treated for 6 to 12 months with a vitamin K antagonist to rivaroxaban (20 mg daily) or placebo for an additional 6 to 12 months.
 
Treatment with rivaroxaban also significantly reduced the risk of recurrent VTE over placebo (P <.001). Nonfatal major bleeding, the safety end point, occurred in four patients in the rivaroxaban group compared with zero in the placebo group (P = .11).
 
These finding were also published online in the New England Journal of Medicine (December 3, 2010).
Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: September 8, 2015